Kura Oncology : Corporate Presentation - February 2023

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER

Corporate Presentation - February 2023

FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitive therapies, and our expectations regarding the therapeutic and commercial potential of our product candidates. The words "believe," "may," "should," "will," "estimate," "promise," "plan", "continue," "anticipate," "intend," "expect," "potential" and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: our preclinical studies and clinical trials may not be successful; the U.S. Food and Drug Administration (FDA) may not agree with our interpretation of the data from clinical trials of our product candidates; we may decide, or the FDA may require us, to conduct additional clinical trials or to modify our ongoing clinical trials; we may experience delays in the commencement, enrollment, completion or analysis of clinical testing for our product candidates, or significant issues regarding the adequacy of our clinical trial designs or the execution of our clinical trials may arise, which could result in increased costs and delays, or limit our ability to obtain regulatory approval; the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; our product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of our product candidates could delay or prevent regulatory approval or commercialization; and we may not be able to obtain additional financing. Additional risks and uncertainties may emerge from time to time, and it is not possible for Kura's management to predict all risk factors and uncertainties.

All forward-looking statements contained in this presentation speak only as of the date on which they were made. Other risks and uncertainties affecting us are described more fully in our filings with the Securities and Exchange Commission. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

2

INVESTMENT HIGHLIGHTS

Targeted	Advancing a pipeline of novel therapies, forging new scientific and clinical paths to give patients a
Oncology	better chance for long-term durable remissions
	Menin Inhibitor Program (ziftomenib)
	• Potential to address 35% or more of acute leukemias
	• Encouraging safety, tolerability and clinical activity observed in relapsed/refractory AML patients
	• 30% CR rate among 20 patients with NPM1 mutations treated at RP2D
Proprietary	• Multiple patients dosed in ongoing Phase 2 registration-directed trial in NPM1-mutant AML
• First combination study with standards of care expected to begin in 1H 2023
Pipeline

Farnesyl Transferase Inhibitor Programs (tipifarnib & KO-2806)

• Durable responses as a monotherapy in recurrent/metastatic HRAS-mutant HNSCC patients
• Proof of mechanism demonstrated in combination with alpelisib in PIK3CA-dependent HNSCC
• Preclinical data support potential to prevent emergence of resistance to targeted therapies
• FDA clearance of IND for KO-2806,next-generation FTI; on track to initiate Phase 1 study in Q3 2023

Strong	•	$25 million strategic equity investment from Bristol Myers Squibb
Financials	•	$438 million in cash as of December 31, 2022* provides runway into Q4 2025

* Cash, cash equivalents and short-term investments

3

KURA LEADERSHIP TEAM AND BOARD OF DIRECTORS

Leadership Team

Troy Wilson, Ph.D., J.D.	Teresa Bair, J.D.	Stephen Dale, M.D.	Kathy Ford
President &	Chief Legal Officer	Chief Medical Officer	Chief Operating Officer
Chief Executive Officer

Francis Burrows, Ph.D.	Pete De Spain	Tom Doyle	Mollie Leoni, M.D.
Senior Vice President,	Senior Vice President, Investor	Senior Vice President,	Senior Vice President,
Translational Research	Relations & Corporate	Finance & Accounting	Clinical Development
	Communications
Board of Directors

Troy Wilson, Ph.D., J.D.	Faheem Hasnain	Helen Collins, M.D.	Thomas Malley
Chairman	Lead Independent Director
Carol Schafer	Steven Stein, M.D.	Diane Parks	Mary Szela	4

DRUG CANDIDATE PIPELINE

PROGRAM	CLINICAL TRIAL	STUDY STARTUP	PHASE 1	REGISTRATION DIRECTED
		NPM1-mutant acute myeloid leukemia (AML)
	KOMET-001	Non-NPM1-m/KMT2A-r AML
	Monotherapy
	(Relapsed/refractory)
		KMT2A-rearranged ALL
ZIFTOMENIB	KOMET-007	NPM1-mutant AML
Menin Inhibitor	Combinations with
ven/aza, 7+3
	(Relapsed/refractory,	KMT2A-rearranged AML
	frontline)
	KOMET-008	NPM1-mutant AML
	Combinations with
	gilteritinib, FLAG-IDA,
	LDAC	KMT2A-rearranged AML
	(Relapsed/refractory)
TIPIFARNIB	KURRENT-HN
Farnesyl	Combination with	PIK3CA-dependent HNSCC
Transferase Inhibitor (FTI)	alpelisib
KO-2806	FIT-001	Solid Tumors
Combinations with
Next-Generation FTI
targeted therapies

5